Compare VMRK & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMRK | IQV |
|---|---|---|
| Founded | 1978 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Real Estate Investment Trusts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.8B | 43.1B |
| IPO Year | 1994 | 2013 |
| Metric | VMRK | IQV |
|---|---|---|
| Price | $62.12 | $266.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 20 |
| Target Price | $71.62 | ★ $309.76 |
| AVG Volume (30 Days) | ★ 4.1M | 1.1M |
| Earning Date | 11-04-2026 | 10-27-2026 |
| Dividend Yield | ★ 4.55% | N/A |
| EPS Growth | ★ 8.09 | 4.67 |
| EPS | 0.54 | ★ 5.24 |
| Revenue | $2,701,075,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $42.39 | $7.12 |
| Revenue Next Year | $51.23 | $6.39 |
| P/E Ratio | $114.33 | ★ $52.36 |
| Revenue Growth | 4.76 | ★ 41.60 |
| 52 Week Low | $58.64 | $154.50 |
| 52 Week High | $66.45 | $284.50 |
| Indicator | VMRK | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 46.98 |
| Support Level | $58.64 | $252.55 |
| Resistance Level | $62.26 | $274.49 |
| Average True Range (ATR) | 1.08 | 9.53 |
| MACD | 0.17 | -0.17 |
| Stochastic Oscillator | 47.55 | 21.45 |
Vivmark owns a high-quality apartment portfolio with around 184,000 units and is developing another $4.4 billion of residential properties. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.